Belarus vs Russian Federation: Average cost of multi drug-resistant tuberculosis treatment
Belarus
2,500 constant 2022 US$
in 2023
Russian Federation
2,751 constant 2022 US$
in 2024
Belarus rank
21st
Russian Federation rank
18th
Average cost of multi drug-resistant tuberculosis treatment over time
- Belarus
- Russian Federation
How they compare
Russian Federation currently reports 2,751 constant 2022 US$ against 2,500 constant 2022 US$ in Belarus, a difference of 251 constant 2022 US$.
That makes Russian Federation's figure about 1.1 times Belarus's.
The two have swapped places 1 time across 5 shared years of data; in 2017 it was Belarus ahead.
Belarus ranks 21st and Russian Federation ranks 18th of 92 countries.
Belarus has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Belarus | Russian Federation | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 5,150 constant 2022 US$ | 2,647 constant 2022 US$ | 2,503 constant 2022 US$ | Belarus |
| 2020s | 3,650 constant 2022 US$ | 2,780 constant 2022 US$ | 870 constant 2022 US$ | Belarus |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Belarus or Russian Federation?
- Russian Federation, at 2,751 constant 2022 US$ against 2,500 constant 2022 US$ in Belarus as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Belarus and Russian Federation?
- 251 constant 2022 US$, with Russian Federation ahead.
- How many years of comparable data are there for Belarus and Russian Federation?
- 5 years are reported by both, from 2017 to 2023.
- How do Belarus and Russian Federation rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Belarus ranks 21st and Russian Federation ranks 18th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.